Dr. Kan Chen is a scientist-turned-investor with a rich background in biotech and biomedical research. As a Partner of Qiming Venture Partners, he co-leads Qiming's investments in the healthcare sector.Before joining Qiming in 2016, he accumulated 12 years of experience at prestigious institutions like the Cleveland Clinic and Harvard Medical School, as well as in major pharmaceutical companies such as Johnson & Johnson and Hengrui Pharma. His expertise spans key disease areas, including cardiovascular diseases, immunology, and cancer. Since joining Qiming, Kan has concentrated on biotech investments, sourcing over 30 deals including many prominent companies. He serves on the boards of more than 20 portfolio companies including Insilico Medicine, LaNova Medicines, and MediLink Therapeutics, and has firsthand experience with public company boards on the NASDAQ, HKEX, and China A-share markets. Kan is well-connected within the US pharma and biotech communities, frequently traveling between the US and China to facilitate strategic transactions between Qiming's portfolio companies and US firms. Kan earned his PhD degree in Cell Biology from Case Western Reserve University in the US and finished his postdoctoral training in Immunology at Harvard Medical School. He received his bachelor's degree in biological sciences from Fudan University.